2020
Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Allogeneic Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial
Gyurkocza B, Nath R, Stiff P, Agura E, Litzow M, Tomlinson B, Choe H, Abhyankar S, Seropian S, Chen G, Hari P, Al-Kadhimi Z, Foran J, Orozco J, van Besien K, Sabloff M, Kebriaei P, Abboud C, Levy M, Lazarus H, Giralt S, Berger M, Reddy V, Pagel J. Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Allogeneic Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial. Transplantation And Cellular Therapy 2020, 26: s32-s33. DOI: 10.1016/j.bbmt.2019.12.575.Peer-Reviewed Original ResearchHematopoietic cell transplantationSalvage therapyOlder patientsCC armConventional careCC patientsConventional hematopoietic cell transplantationGrade 3 febrile neutropeniaAllogeneic hematopoietic cell transplantationPre-treated patientsPhase 3 trialFailure of chemotherapyYears of ageFebrile neutropeniaInduction therapyActive diseaseMyeloablative conditioningRefractory AMLBackground PatientsBM blastsInfusion reactionsMethods PatientsTransplant candidatesAllogeneic transplantationCurative therapy
2009
Autologous and allogeneic transplantation for aggressive T-cell lymphomas: A single institution experience
Lansigan F, Cooper D, Seropian S, Foss F. Autologous and allogeneic transplantation for aggressive T-cell lymphomas: A single institution experience. Journal Of Clinical Oncology 2009, 27: 8558-8558. DOI: 10.1200/jco.2009.27.15_suppl.8558.Peer-Reviewed Original ResearchAggressive T-cell lymphomaProgression-free survivalT-cell lymphomaAuto groupFirst remissionBetter progression-free survivalAggressive B-cell lymphomasMedian prior therapiesNon-relapse mortalitySingle institution experienceRole of transplantationNon-Hodgkin lymphomaLarge cell transformationB-cell lymphomaAllo transplantPrior therapyRelapse mortalityRelapsed diseaseALLO groupPoor OSAllogeneic transplantationLymphoblastic lymphomaMedian ageMedian timeWorse prognosis